NovoCure (NASDAQ: NVCR)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
NovoCure Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
NovoCure Company Info
Novocures tumor-treating field devices use electric fields to disrupt the replication of cancer cells.
News & Analysis
Investors were looking for a stronger Q4 from the cancer company.
There was good news from the laboratory on Hump Day.
Investors reacted negatively to the oncology treatment specialist's game of C-suite musical chairs.
The stock has both soared and sank already this year.
The company provided a disappointing sneak peek at its Q4 results.
Successful clinical trial results recently pushed this stock more than 68% higher overnight -- but what about the road ahead?
Here's why Novocure stock popped over 68% on Jan. 5.
The company announced good news from a late-stage study of its Tumor Treating Fields therapy.
The cancer-focused medical-device maker received the go-ahead to enter a brand-new market. Here's why the news should make investors giddy.
Medical devices can be ultra reliable, lucrative business, but there are plenty of ways for companies to blow it, too.
Recurring revenue, monopolistic market positions, and returns that tend to beat even the risky biotechs tie these three together.
NVCR earnings call for the period ending December 31, 2022.
NVCR earnings call for the period ending September 30, 2022.
NVCR earnings call for the period ending June 30, 2022.
NVCR earnings call for the period ending March 31, 2022.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.